HF
ANTX icon

HRT Financial’s AN2 Therapeutics ANTX Stock Holding History

HRT Financial’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$112K Buy
+32,924
New +$67.9K ﹤0.01% 3329
2025
Q3 		– Sell
-12,678
Closed -$13K – 2824
2025
Q2 		$13K Buy
+12,678
New +$15.1K ﹤0.01% 2433
2024
Q2 		– Sell
-24,366
Closed -$79K – 2173
2024
Q1 		$79K Buy
+24,366
New +$265K ﹤0.01% 1883

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

HRT Financial's ANTX Position: Q1 2026 in Review

HRT Financial opened a new position in AN2 Therapeutics (ANTX) in Q1 2026: 32,924 shares worth $112K. The stake represents ﹤0.01% of the portfolio and ranks #3329 among its holdings. This is a return to the name: HRT Financial previously reported a position in ANTX as recently as Q2 2025.

HRT Financial first reported a position in ANTX in Q1 2024 and has held it in 3 quarters since. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • HRT Financial held 32,924 shares of AN2 Therapeutics worth $112K as of Q1 2026.
  • AN2 Therapeutics was a new HRT Financial position in Q1 2026.
  • AN2 Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3329 holding.
  • HRT Financial first reported a position in AN2 Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.